Showing results for: molecular diagnostics News
-
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced the closing of a definitive asset purchase agreement under which Flagship Biosciences, Inc. has acquired the Company’s Pharma Services business (Interpace Pharma Solutions). The Company will use the proceeds from the transaction for ...
-
Invitation to the Annual Shareholders’ Meeting
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), has the honor to invite its shareholders, holders of subscription rights, holders of convertible bonds, directors and statutory auditor to its annual shareholders' meeting (‘AGM’) that will be held on Friday 13 May 2022 at 2:00 p.m. CEST at ...
By Biocartis NV
-
Abbott Molecular distribution of ELITechGroup products will expand distribution channels
ELITechGroup today announced a distribution agreement with Abbott Molecular, Inc. for U.S. distribution of molecular diagnostic reagents. The reagents included in the agreement are focused on monitoring virus activity in patients that have undergone organ or hematopoietic stem cell transplantation. Other products included in the agreement will focus on the expanding need to test for additional ...
By ELITechGroup
-
Quidel to Present at 40th Annual J.P. Morgan Healthcare Conference
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference to be held virtually on Wednesday, January 12, 2022. Douglas Bryant, president and chief executive officer, will present that day at 1:30 p.m. Eastern time (10:30 ...
-
Quidel to Hold Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 17th, 2022
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year 2021 financial results after market close on Thursday, February 17, 2022. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial ...
-
Anavasi Diagnostics Announces Appointment of Scott Robitaille As Vice President Of Sales And Marketing
Anavasi Diagnostics ('Anavasi'), a medical technology company focused on the development of novel molecular diagnostic testing, has announced the addition of Scott Robitaille as Vice President of Sales & Marketing. Robitaille joins Anavasi with in-depth knowledge of the medical device and molecular diagnostics sector and over two decades of sales, marketing, and channel management ...
-
2020 End of Year Summary
Research Triangle Park, North Carolina, December 31st, 2020 – Redbud Labs (“Redbud”) closed out an active year for new product development. Early in 2020, Redbud Labs announced its ISO certification and an expansion of its product lines. Responding to the COVID-19 outbreak, Redbud adjusted its operating plans and began new internal R&D projects. The company’s ...
By Redbud Labs
-
Anavasi Diagnostics Announces FDA EUA Submission for Its COVID-19 Test
Anavasi Diagnostics announced today that it has submitted the required EUA Clinical Study Data for the AscencioDx®, the molecular diagnostic platform for the detection of RNA indicative of the presence of the SARS-CoV-2/COVID-19 virus, to the Food and Drug Administration (FDA). Anavasi is a medical technology company focused on the development of novel molecular diagnostic testing. It uses a ...
-
Sherlock Biosciences Strengthens Intellectual Property Portfolio in CRISPR-based Diagnostics Through Exclusive License Agreement with Tolo Biotech
Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced exclusive license agreements with Shanghai-based Tolo Biotech. Tolo has granted Sherlock exclusive rights in the United States to its CRISPR-Cas12 (including Cas12a and Cas12b) diagnostic technology, and Sherlock has granted Tolo exclusive rights to the ...
-
Abbott joins clinton health access initiative in effort to improve infant testing for HIV in Africa
Abbott and the Clinton Health Access Initiative (CHAI) have joined forces to provide HIV testing to infants in all countries working in partnership with the CHAI. A key focus of this cooperation will be sub-Saharan Africa, which the World Health Organization estimates to account for 90 percent of global HIV infections in children. Under terms of the agreement, Abbott will supply its RealTime ...
-
HiberGene Diagnostics introduces brand new UK division at NEQAS event
HiberGene Diagnostics, the leading manufacturer of molecular diagnostics products in Ireland, is pleased to announce that it will supply its innovative point-of-care (POC) and near-patient testing solutions directly to healthcare providers in the UK and Ireland. These high-quality testing solutions cover infectious and transmissible disease areas – including respiratory, sexually ...
-
ELITechGroup Molecular Diagnostics announce the CE-IVD marking of the CRE ELITe MGB Kit, for the detection of the Carbapenem Resistance genes of Enterobacteriaceae
ELITechGroup Molecular Diagnostics announce today the CE-IVD marking of the CRE ELITe MGB kit, a high-performance, qualitative, multiplex assay for the rapid detection of the Carbapenem Resistance genes of Enterobacteriaceae. In combination with the ELITe InGenius™, the ELITech Group’s fully automated sample-to-result system, the assay is intended to detect 150 variants belonging to ...
By ELITechGroup
-
Berkshire and Surrey Pathology Services & ONCODNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK
DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED: “In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation sequencing. This unique public-private ...
By OncoDNA S.A.
-
Pacific Edge Appoints Dr Peter Meintjes As Its New CEO
Pacific Edge today announces the appointment of Dr Peter Meintjes, an experienced molecular diagnostics and genomics business leader, as its new Chief Executive Officer. Dr Meintjes, a New Zealand citizen currently resident in Boston, brings to Pacific Edge extensive global diagnostics, biotechnology, and commercial leadership expertise. He also has a track record for commercialising new and ...
-
Inflammatix Appoints Dr. Kian Beyzavi as New Board Member
Inflammatix, a pioneering molecular diagnostics company, announced today the appointment of Kian Beyzavi, PhD, as an independent member of the company’s board of directors. Dr. Beyzavi is a seasoned veteran of the healthcare industry with significant operating experience in the medical device and diagnostics industries, and a focus on leveraging innovative technologies to improve diagnosis ...
-
Quadrant Biosciences Receives Breakthrough Device Designation for Novel Autism Saliva Test
Quadrant Biosciences Inc., a developer of novel molecular diagnostic tools, has been granted a Breakthrough Device designation by the Center of Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for its innovative Clarifi ASD® autism saliva test. Clarifi ASD is indicated for use in assessing the likelihood that a child has autism spectrum disorder (ASD) based on ...
-
BillionToOne Launches Novel Fetal Antigen NIPT as Part of UNITY Screen
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. For pregnant patients who are alloimmunized with C, c, D, E, Duffy (Fya), or Kell (K) red blood cell (RBC) antibodies, this novel NIPT ...
-
Visby Medical Appoints Everett Cunningham to Board of Directors
Visby Medical™, a leading medical diagnostic company, today announced Everett Cunningham has been appointed to the company’s Board of Directors. Cunningham is currently Chief Commercial Officer at Exact Sciences and brings 30 years of commercial experience in pharmaceuticals and molecular diagnostics to the company’s board. “I am thrilled to welcome Everett to the Visby ...
-
New Rapid Molecular COVID-19 Test from Anavasi Diagnostics Awarded $14.9 Million by NIH to Accelerate Test Availability
Anavasi Diagnostics, a medical technology company focused on the development of novel molecular diagnostic testing using a proprietary patent-pending reverse transcriptase methodology, today announced it has been awarded $14.9 million from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative. The funding will accelerate the launch and broad market ...
-
Great Basin and Rice University Announce Collaboration to Optimize the Design of SARS-CoV-2 Molecular Assays
Great Basin Scientific, a molecular diagnostics company, and Dr. Todd Treangen’s bioinformatics group in the Department of Computer Science at Rice University (www.treangenlab.com), today announced a co-development partnership that is optimizing the design and in silico evaluation of molecular detection assays for the SARS-CoV-2 viral RNA, the pathogen that causes COVID-19. The aim of the ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you